Scale Biosciences and Revvity’s BioLegend Launch First-of-its-Kind Solution for High Parameter Protein Profiling of Single Cells
Scale Biosciences (Scale BioTM), a leader in innovative and scalable single cell analysis solutions, and Revvity’s (
NYSERVTY) BioLegend business, a leading provider of world-class biological reagents and tools, today announced the availability of a new, first-of-its-kind TotalSeqTM PhenocyteTM single-cell protein profiling solution that supports customers by more easily identifying and characterizing rare cell subtypes, which ultimately powers immunology and oncology research. The solution is enabled by the proprietary combination of Scale Biosciences’ Quantum Barcoding technology platform and BioLegend’s TotalSeqTM antibody conjugates.
Scale Bio Draws Nearly 1 Billion Cells in Global Health and Disease Research Challenge
In an exciting moment for genomics research, Scale Biosciences (Scale Bio) announced today the winning projects of the 100 Million Cell Challenge representing more than a dozen projects addressing critical challenges in global health — from childhood respiratory diseases to cancer disparities. These projects, chosen from 147 proposals submitted across 27 countries, represent a total of 50 million cells and will be fully subsidized by the Chan Zuckerberg Initiative (CZI). The selected projects span a remarkable range of applications, from expanding the first global atlas of pediatric health to investigating population-specific differences in cancer outcomes. Collectively, they demonstrate how increased scale in single cell analysis can transform our understanding of human biology and disease.
Chan Zuckerberg Initiative Joins Scale Bio's '100 Million Cell Challenge' to Accelerate Single Cell Genomics Research
Scale Biosciences (Scale Bio), a leader in innovative and scalable single cell analysis solutions, today announced that the Chan Zuckerberg Initiative (CZI) has joined as a partner in the groundbreaking '100 Million Cell Challenge.' CZI will fully subsidize support for 50 million cells' worth of awarded projects. This partnership comes on the heels of an overwhelming response to the challenge, with researchers pledging to analyze over 100 million cells within days of the initial announcement.
Quantum Leap in Single Cell Genomics: Scale Bio Launches Groundbreaking ‘100 Million Cell Challenge’ in Collaboration with Ultima Genomics and NVIDIA
Scale Biosciences (Scale Bio), a leader in innovative and scalable single cell analysis solutions, today announced the launch of the “100 Million Cell Challenge,” a global initiative aimed at pushing the boundaries of single-cell genomics research.
Scale Biosciences Announces ScalePlex Technology to Simplify Single Cell Genomics Studies of Any Scale
Scale Biosciences (ScaleBioTM), an innovator in accessible, flexible, and scalable single cell omics solutions, today announced the availability of ScalePlex an advanced single cell multiplexing technology designed to simplify large-scale single cell genomics studies. With massively parallelized single cell barcoding and effortless sample multiplexing, ScalePlex enables ultimate experimental flexibility from small to large-scale, multi-sample, multi-condition studies while generating high quality data.
Scale Biosciences Unveils Platform for Dramatic Scaling of Single-Cell Experiments and Announces Partnerships to Drive Ease of Use and Enable New Biological Insights
Scale Biosciences (ScaleBio™), an innovator in exponentially scaled single-cell sequencing, providing instrument-free workflows and accessible cost, today announced its development of a new two plate workflow to enable dramatic scaling of its technology and a first set of partners to improve ease of use and enable the deployment of their portfolio across new omics applications. The new platform, announced at the 2024 Advances in Genome Biology and Technology (AGBT) general meeting being held February 5-8, 2024 in Orlando, Fla., allows researchers to prepare sequencing-ready single-cell libraries of up to 2 million cells in a experiment and reduces the plates needed from three to two. This technology will form the basis for future ScaleBio innovation and product development.
Scale Biosciences Announces Progress Across Growing Portfolio of Single-Cell Omics Solutions
Scale Biosciences (ScaleBio™), an innovator in exponentially scaled single-cell sequencing, providing instrument-free workflows and accessible cost, today announced the availability of three new datasets showcasing the performance of its newly released products, including the ScaleBio Single Cell Methylation Kit, ScaleBio Single Cell RNA Kit v1.1 with extended throughput, and ScaleBio CRISPR Guide Enrichment Kit, all of which are now shipping. The datasets are available for download on the ScaleBio website, and in addition, the RNA dataset is available in the Chan Zuckerberg Cell by Gene Discover database.
Scale Biosciences and Basepair to Democratize Single Cell Sequencing Data Analysis
Scale Biosciences, a pioneer in single-cell sequencing technology, today announced a new collaboration with Basepair to provide point and click bioinformatic analysis of single-cell data produced with its patented and disruptive combinatorial indexing technology. As a result of this collaboration, scientists will be able to access Scale Biosciences’ optimized bioinformatics pipeline through a user-friendly, web-based, graphical user interface (GUI), enabling their organizations to quickly adopt new single-cell protocols, regardless of their in-house bioinformatics capabilities.
